Antimicrobial resistance: develop solutions in the UK

Overview of the UK's antimicrobial resistance (AMR) research infrastructure and advantages of investment in the UK's life science sector to support new treatments.



A summary of the UK’s strengths as centre for AMR, including:

  • reasons to select the UK as a partner for development
  • information on infrastructure for treatment, diagnostics and systems research and development
  • information on risk reduction and efficient routes to product development
Published 15 October 2018